APA (7th ed.) Citation

P, M., D, G., G, F., Y, Ü., MT, B., A, S., . . . M, S. (2025). 177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study. European journal of cancer (Oxford, England : 1990), 229, 115789. https://doi.org/10.1016/j.ejca.2025.115789

Chicago Style (17th ed.) Citation

P, Mandel, et al. "177Lu-PSMA Vs. Cabazitaxel in Patients with Castration-resistant Prostate Cancer: Real-world Efficacy and Safety Data from the ARON-3 Study." European Journal of Cancer (Oxford, England : 1990) 229 (2025): 115789. https://doi.org/10.1016/j.ejca.2025.115789.

MLA (9th ed.) Citation

P, Mandel, et al. "177Lu-PSMA Vs. Cabazitaxel in Patients with Castration-resistant Prostate Cancer: Real-world Efficacy and Safety Data from the ARON-3 Study." European Journal of Cancer (Oxford, England : 1990), vol. 229, 2025, p. 115789, https://doi.org/10.1016/j.ejca.2025.115789.